News | November 04, 2024
Briefs: Sun Pharmaceutical Industries and Biocon Biologics
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Subscribe To Our Newsletter & Stay Updated
